The role of leukocytes in myeloproliferative neoplasm thromboinflammation
Journal of Leukocyte Biology · 29.05.2024 · 115 (6) · 1020-1028
DOI: 10.1093/jleuko/qiae071 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Leukocyte Biology, online erschienen am 25.03.2024. Verfasst von Yu Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Zhongnan Hospital of Wuhan University, 169, East Lake Road, Wuchang District, Wuhan 430071, China. Hauptthemen laut MEDLINE: Myeloproliferative Disorders, Thrombosis, Leukocytes, Inflammation. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Classic myeloproliferative neoplasms lacking the Philadelphia chromosome are stem cell disorders characterized by the proliferation of myeloid cells in the bone marrow and increased counts of peripheral blood cells. The occurrence of thrombotic events is a common complication in myeloproliferative neoplasms. The heightened levels of cytokines play a substantial role in the morbidity and mortality of these patients, establishing a persistent proinflammatory condition that culminates in thrombosis. The etiology of thrombosis remains intricate and multifaceted, involving blood cells and endothelial dysfunction, the inflammatory state, and the coagulation cascade, leading to hypercoagulability. Leukocytes play a pivotal role in the thromboinflammatory process of myeloproliferative neoplasms by releasing various proinflammatory and prothrombotic factors as well as interacting with other cells, which contributes to the amplification of the clotting cascade and subsequent thrombosis. The correlation between increased leukocyte counts and thrombotic risk has been established. However, there is a need for an accurate biomarker to assess leukocyte activation. Lastly, tailored treatments to address the thrombotic risk in myeloproliferative neoplasms are needed. Therefore, this review aims to summarize the potential mechanisms of leukocyte involvement in myeloproliferative neoplasm thromboinflammation, propose potential biomarkers for leukocyte activation, and discuss promising treatment options for controlling myeloproliferative neoplasm thromboinflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, Zhongnan Hospital of Wuhan University, 169, East Lake Road, Wuchang District, Wuhan 430071, China.
- Department of Immunology, College of Basic Medicine, Chongqing Medical University, Yixueyuan Road, Yuzhong District, Chongqing 400016, P.R. China.
- Department of Cell Systems & Anatomy, Department of Pathology & Laboratory, Medicine UT Health San Antonio, Joe R. and Teresa Lozano Long School of Medicine, 8403 Floyd Curl Drive, San Antonio, TX 78229, United States.
- Biomedical Sciences Graduate Program, Ohio State University, Columbus, OH 43210, United States.
Zitieren
APA
Liu, Y., Wang, Y., Huang, G., Wu, S., Liu, X., Chen, S., Luo, P., Liu, C., & Zuo, X. (2024). The role of leukocytes in myeloproliferative neoplasm thromboinflammation. Journal of Leukocyte Biology, 115(6), 1020-1028. https://doi.org/10.1093/jleuko/qiae071
Vancouver
Liu Y, Wang Y, Huang G, Wu S, Liu X, Chen S, et al. The role of leukocytes in myeloproliferative neoplasm thromboinflammation. Journal of Leukocyte Biology. 2024;115(6):1020-1028. doi:10.1093/jleuko/qiae071
BibTeX
@article{Liu2024,
author = {Liu, Yu and Wang, Yingying and Huang, Gang and Wu, Sanyun and Liu, Xiaoyan and Chen, Shuo and Luo, Ping and Liu, Chang and Zuo, Xuelan},
title = {The role of leukocytes in myeloproliferative neoplasm thromboinflammation},
journal = {Journal of Leukocyte Biology},
year = {2024},
volume = {115},
number = {6},
pages = {1020--1028},
doi = {10.1093/jleuko/qiae071}
}
EUVIMED